BioDelivery Sciences (BDS) Announces $1.3M U.S. Army Grant
More News related to BDSI
- BioDelivery Sciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Meda Launches Onsolis(TM) (Fentanyl Buccal Soluble Film) for the Treatment of Breakthrough Cancer Pain in Opioid Tolerant Patients
- BioDelivery Sciences International, Inc. (BDSI) President and Chief Executive Officer to Ring The NASDAQ Stock Market Opening Bell
- BioDelivery Sciences and Meda Launch ONSOLIS (fentanyl buccal soluble film)
- BioDelivery Sciences (BDS) Announces $1.3M U.S. Army Grant
More News related to Corporate News
- Waterside Capital (WSCC) Reports a Quarterly Loss
- Ship Finance (SFL) Posts Q3 adj.-EPS of $0.47, Misses Estimates
- Frontline (FRO) Posts Q3 Loss of $0.07, Beats Street by 5c
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) received a $1.3 million grant from the Walter Reed Army Institute of Research for Bioral Amphotericin B, an oral formulation of the fungicidal treatment amphotericin B in BDSI’s patented Bioral drug delivery technology, to further study the formulation in the treatment of Cutaneous Leishmaniasis.
Related Categories
Corporate NewsStocks Mentioned
-0.07Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
